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doi:10.1016/j.jtcvs.2006.05.013n this issue of the Journal, Acker and colleagues1 present some of the outcomes
of the CorCap study—specifically, the subgroup analysis of patients who
underwent concomitant mitral valve surgery. In this randomized study, the
ddition of the CorCap device provided enhanced geometric changes in the left
entricular (LV) shape without having a significant additive effect on clinical
utcomes.
The most notable information contained in this dataset is the outcomes of the
ontrol group: mitral valve surgery in medically optimized patients with significant
unctional mitral regurgitation, myopathic hearts, and symptomatic congestive heart
ailure. This subgroup represents an uncontrolled prospective analysis of isolated
itral valve surgery in patients with significant functional mitral insufficiency, New
ork Heart Association class III or IV, ejection fraction less than 35% (mean
jection fraction, 23%  9%), and a dilated LV (mean LV end-diastolic volume,
70.1  100.3 mL). This group had an outstanding 1.6% 30-day mortality rate and
ignificant improvements in quality of life, exercise performance, and New York
eart Association functional class. Equally as important, mitral valve operations led
o improvements in LV volumes, mass, and shape, all consistent with reverse
emodeling. Finally, unlike other reports in the literature, the operations were
urable, because recurrence of clinically significant MR was uncommon in this
atient cohort.2 As a result, the authors conclude that the improvement in LV
tructure and clinical function, along with a very low mortality rate, justifies strong
onsideration for offering MV surgery to heart failure patients who are on an
ptimal medical regimen.
These are excellent results, and from the perspective of the CorCap, it would be
ard to measure any additional clinical benefit from the CorCap device that would
dvocate its addition to mitral valve surgery. The outcomes do, however, support the
ypothesis that patients with cardiomyopathy benefit from the surgical correction of
he functional mitral insufficiency. The results of this study add to a growing
xperience of clinical improvement with mitral valve repair.3 Unfortunately, there
till is considerable skepticism about the safety and efficacy of mitral valve surgery
n patients with heart failure. Earlier this year, the American College of Cardiology
ublished a continuing medical education course entitled “Mitral Valve Surgery for
HF: A Failed Concept?” which taught that “surgical treatment of FMR results in
ittle if any survival benefit or reverse remodeling” and “it is possible that MVR for
MR reduces symptoms and improves exercise tolerance but conclusive data to
upport this hypothesis do not exist.”4 The course went on to conclude that “the
vailable data suggest that the current enthusiasm for surgical treatment of FMR
hould be reconsidered until the results of a prospective trial confirms its efficacy.”
ast year, another study, although nonrandomized and retrospective, failed to show
survival benefit in a similar patient cohort.5 As recently as 1998, American Heart
ssociation/American College of Cardiology guidelines even questioned the appro-
riateness of surgical therapy in these patients. “Determining the surgical candidacy
f the symptomatic patient with MR and far-advanced LV dysfunction is a common
linical dilemma. If mitral valve repair appears likely, surgery should still be
ontemplated, provided ejection fraction is 30%.”6 Last year, this approach was
till considered “under development” by American Heart Association/American
ollege of Cardiology guidelines for the treatment of heart failure.7
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LAlthough the current patient cohort is not randomized
gainst medical therapy, the study does directly address the
receding concerns with data from a prospective, multi-
enter, observational study. This provides strong data to
ounter the strong negative impression in the community of
he surgical treatment outcomes of MR in patients with
mpaired LV function. There are several things that we do not
earn from this study. First, there is no medical control arm to
bsolutely determine the benefit of mitral valve surgery. Sec-
nd, one is unable to extend these findings to patients with
unctional ischemic mitral insufficiency, because greater than
0% of these patients had nonischemic cardiomyopathies. Fi-
ally, no insights can be gleaned as to which patients benefit
rom mitral repair over mitral replacement or the ability to
redict in which patients valve repair is likely to fail.
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